Biological ActivitySelective HIF-1 dimerization inhibitor. Blocks protein-protein interaction of recombinant HIF-1α, but not HIF-2α, with HIF-1β (IC50 = 1.3 μM). Inhibits hypoxia-induced HIF-1 activity, and decreases VEGF and CAIX expression in osteosarcoma and breast cancer cells in vitro. Also reduces tubularization of hypoxic HUVECs.
(Modifications: Lactam bridge: Cys-1 to Tyr-6), Disulfide bridge: 1-1*)
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis. All Tocris products are intended for laboratory research use only.
A Cyclic Peptide Inhibitor of HIF-1 Heterodimerization That Inhibits Hypoxia Signaling in Cancer Cells.
Miranda E, Nordgren IK, Male AL et al.
J Am Chem Soc
No product specific FAQs exist for this product, however you mayView all Peptide FAQs
Reviews for TAT-cyclo-CLLFVY
There are currently no reviews for this product. Be the first to review TAT-cyclo-CLLFVY and earn rewards!
Have you used TAT-cyclo-CLLFVY?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image